As of 2024-12-13, the EV/EBITDA ratio of ANI Pharmaceuticals Inc (ANIP) is -28.52. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ANIP's latest enterprise value is 1,669.27 mil USD. ANIP's TTM EBITDA according to its financial statements is -58.52 mil USD. Dividing these 2 quantities gives us the above ANIP EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.6x - 9.8x | 9.6x |
| Forward P/E multiples | 9.8x - 10.4x | 10.2x |
| Fair Price | (46.91) - 10.50 | (19.93) |
| Upside | -182.9% - -81.4% | -135.2% |
| Date | EV/EBITDA |
| 2024-12-11 | -29.46 |
| 2024-12-10 | -29.46 |
| 2024-12-09 | -29.05 |
| 2024-12-06 | -28.67 |
| 2024-12-05 | -28.32 |
| 2024-12-04 | -28.63 |
| 2024-12-03 | -28.64 |
| 2024-12-02 | -28.99 |
| 2024-11-29 | -28.76 |
| 2024-11-27 | -29.54 |
| 2024-11-26 | -28.99 |
| 2024-11-25 | -29.27 |
| 2024-11-22 | -28.65 |
| 2024-11-21 | -28.27 |
| 2024-11-20 | -28.00 |
| 2024-11-19 | -28.21 |
| 2024-11-18 | -28.05 |
| 2024-11-15 | -28.53 |
| 2024-11-14 | -29.37 |
| 2024-11-13 | -29.70 |
| 2024-11-12 | -30.12 |
| 2024-11-11 | -30.38 |
| 2024-11-08 | -30.28 |
| 2024-11-07 | -29.18 |
| 2024-11-06 | -29.18 |
| 2024-11-05 | -28.79 |
| 2024-11-04 | -28.33 |
| 2024-11-01 | -29.11 |
| 2024-10-31 | -28.77 |
| 2024-10-30 | -29.22 |
| 2024-10-29 | -29.40 |
| 2024-10-28 | -29.03 |
| 2024-10-25 | -29.16 |
| 2024-10-24 | -29.50 |
| 2024-10-23 | -29.41 |
| 2024-10-22 | -29.79 |
| 2024-10-21 | -29.50 |
| 2024-10-18 | -29.87 |
| 2024-10-17 | -29.80 |
| 2024-10-16 | -29.64 |
| 2024-10-15 | -29.26 |
| 2024-10-14 | -29.22 |
| 2024-10-11 | -28.73 |
| 2024-10-10 | -28.00 |
| 2024-10-09 | -28.58 |
| 2024-10-08 | -28.61 |
| 2024-10-07 | -28.27 |
| 2024-10-04 | -28.98 |
| 2024-10-03 | -28.61 |
| 2024-10-02 | -28.86 |